Search Results for: 58

Theriva™ Biologics Reports Full-Year 2023 Operational Highlights and Financial Results

March 25, 2024 07:30 ET – The independent data monitoring committee (IDMC) recommended the continuation of VIRAGE, the Phase 2b clinical trial of VCN-01 in combination with chemotherapy for metastatic Pancreatic Ductal Adenocarcinoma (PDAC), with no safety concerns raised – – VIRAGE remains on track to complete enrollment in the first half of 2024- – […]

Theriva™ Biologics Reports Full-Year 2023 Operational Highlights and Financial Results Read More »

Theriva™ Biologics presenta los aspectos operativos más destacados y los resultados financieros de todo el ejercicio 2023

March 25, 2024 07:30 ET – El Comité independiente para la monitorización de los datos (IDMC) ha recomendado la continuación de VIRAGE, ensayo clínico de fase 2b de VCN-01, en combinación con quimioterapia para el adenocarcinoma ductal pancreático (PDAC) metastásico, sin que se plantearan problemas de seguridad – – VIRAGE está en vías de finalizar la

Theriva™ Biologics presenta los aspectos operativos más destacados y los resultados financieros de todo el ejercicio 2023 Read More »

Theriva™ Biologics Reports Third Quarter 2023 Operational Highlights and Financial Results

November 13, 2023 08:00 ET – VIRAGE, the Phase 2b clinical trial of VCN-01 in combination with chemotherapy for metastatic Pancreatic Ductal Adenocarcinoma remains on track to complete enrollment in the first half of 2024; multiple patients have received second doses of VCN-01, which continues to be well tolerated with a safety profile consistent with

Theriva™ Biologics Reports Third Quarter 2023 Operational Highlights and Financial Results Read More »

Theriva™ Biologics presenta los aspectos operativos más destacados y los resultados financieros del tercer trimestre de 2023

November 13, 2023 08:00 ET – VIRAGE, el ensayo clínico de fase 2b de VCN-01 en combinación con quimioterapia para el adenocarcinoma ductal de páncreas metastásico, sigue el curso previsto para completar la inscripción en el primer semestre de 2024; muchos pacientes han recibido la segunda dosis de VCN-01, que sigue siendo bien tolerado y mantiene

Theriva™ Biologics presenta los aspectos operativos más destacados y los resultados financieros del tercer trimestre de 2023 Read More »

Theriva™ Biologics Presents Survival Outcomes Data from Phase 1 Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck at ESMO Congress 2023

October 23, 2023 07:00 ET -Results show enhanced patient survival, correlating with VCN-01 mediated increases in the CPS score, a key determinant of outcomes with anti-PD-(L)1 checkpoint inhibitor therapies- -Key Opinion Leader (KOL) webinar featuring expert oncologist Ricard Mesia M.D., Ph.D., to be held today, Monday, October 23, 2023 at 8:00 a.m. ET- ROCKVILLE, Md.,

Theriva™ Biologics Presents Survival Outcomes Data from Phase 1 Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck at ESMO Congress 2023 Read More »

Theriva™ Biologics Announces Presentation at ESMO Congress 2023 Featuring Survival Outcomes in Phase 1 Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

October 16, 2023 08:00 ET -Results from investigator-sponsored study in collaboration with the Institut Catala d’Oncologia (ICO) show enhanced patient survival, correlating with VCN-01 induced upregulation of PD(L)-1- -Key Opinion Leader (KOL) webinar featuring expert oncologist Ricard Mesia M.D., Ph.D., to be held Monday, October 23, 2023 at 8:00 a.m. ET- ROCKVILLE, Md., Oct. 16,

Theriva™ Biologics Announces Presentation at ESMO Congress 2023 Featuring Survival Outcomes in Phase 1 Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck Read More »

Theriva™ Biologics Announces Key Progress in VIRAGE, an Ongoing, Multinational Phase 2b Trial of VCN-01 in Combination with Chemotherapy in Pancreatic Ductal Adenocarcinoma

– Initiated dosing at U.S. sites for VIRAGE – – Second doses of intravenous VCN-01 administered to patients in Spain and were well tolerated – – VIRAGE remains on track to complete enrollment in the first quarter of 2024 – ROCKVILLE, Md., Aug. 02, 2023 (GLOBE NEWSWIRE) — Theriva™ Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a

Theriva™ Biologics Announces Key Progress in VIRAGE, an Ongoing, Multinational Phase 2b Trial of VCN-01 in Combination with Chemotherapy in Pancreatic Ductal Adenocarcinoma Read More »

Theriva™ Biologics Announces Appointment of Ramon Alemany, Ph.D., to Senior Vice President of Discovery

May 23, 2023 08:00 ET -Appointment expected to aid advancement of Theriva’s discovery program and strengthen collaboration with the Institut Catala d’Oncologia (ICO) and the Biomedical Research Institute of Bellvitge (IDIBELL)- ROCKVILLE, Md., May 23, 2023 (GLOBE NEWSWIRE) — Theriva Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a clinical-stage company developing therapeutics designed to

Theriva™ Biologics Announces Appointment of Ramon Alemany, Ph.D., to Senior Vice President of Discovery Read More »

Theriva Biologics anuncia el nombramiento del Dr. Ramón Alemany en el cargo de vicepresidente sénior de descubrimiento de fármacos

May 23, 2023 15:40 ET -Con este nombramiento se espera contribuir al avance del programa de descubrimiento de Theriva y al fortalecimiento de la colaboración con el Institut Català d’Oncologia (ICO) y el Institut d’Investigació Biomèdica de Bellvitge (IDIBELL)- ROCKVILLE, Maryland, May 23, 2023 (GLOBE NEWSWIRE) — Theriva Biologics (NYSE American: TOVX), («Theriva» o la

Theriva Biologics anuncia el nombramiento del Dr. Ramón Alemany en el cargo de vicepresidente sénior de descubrimiento de fármacos Read More »